Zobrazeno 1 - 10
of 90
pro vyhledávání: '"Ulka Vaishampayan"'
Autor:
Benjamin Garmezy, Ulka Vaishampayan
Publikováno v:
Oncology and Therapy, Vol 12, Iss 4, Pp 647-661 (2024)
Abstract In recent years, the armamentarium of therapies for the management of advanced renal cell carcinoma (aRCC) has grown. Combination therapies, including immuno-oncology (IO) agents and tyrosine kinase inhibitors [TKIs (IO–TKI)], and IO–IO
Externí odkaz:
https://doaj.org/article/da00f9f32c5241088dd07e9cc433701f
Autor:
Barani Govindarajan, Diego Sbrissa, Mark Pressprich, Seongho Kim, Arun K. Rishi, Ulka Vaishampayan, Michael L. Cher, Sreenivasa R. Chinni
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract The chemokine receptor, CXCR4 signaling regulates cell growth, invasion, and metastasis to the bone-marrow niche in prostate cancer (PCa). Previously, we established that CXCR4 interacts with phosphatidylinositol 4-kinase IIIα (PI4KIIIα en
Externí odkaz:
https://doaj.org/article/72f203e958aa4b8ca95a10b6d2a6edb9
Autor:
Dejan Juric, Minal Barve, Ulka Vaishampayan, Desamparados Roda, Aitana Calvo, Noelia Martinez Jañez, Jose Trigo, Alastair Greystoke, R. Donald Harvey, Anthony J. Olszanski, Mateusz Opyrchal, Alexander Spira, Fiona Thistlethwaite, Begoña Jiménez, Jessica Huck Sappal, Karuppiah Kannan, Jason Riley, Cheryl Li, Cong Li, Richard C. Gregory, Harry Miao, Shining Wang
Publikováno v:
Cancer Medicine, Vol 13, Iss 5, Pp n/a-n/a (2024)
Abstract Mivavotinib (TAK‐659/CB‐659), a dual SYK/FLT3 inhibitor, reduced immunosuppressive immune cell populations and suppressed tumor growth in combination with anti‐PD‐1 therapy in cancer models. This dose‐escalation/expansion study inv
Externí odkaz:
https://doaj.org/article/543c6b5130f7472f8fd3b9ea9ea6f7e2
Autor:
Cassandra Duarte, Junxiao Hu, Benoit Beuselinck, Justine Panian, Nicole Weise, Nazli Dizman, Katharine A. Collier, Nityam Rathi, Haoran Li, Roy Elias, Nieves Martinez-Chanza, Tracy L. Rose, Lauren C. Harshman, Dharmesh Gopalakrishnan, Ulka Vaishampayan, Yousef Zakharia, Vivek Narayan, Benedito A. Carneiro, Anthony Mega, Nirmish Singla, Cheryl Meguid, Saby George, James Brugarolas, Neeraj Agarwal, Amir Mortazavi, Sumanta Pal, Rana R. McKay, Elaine T. Lam
Publikováno v:
EClinicalMedicine, Vol 60, Iss , Pp 102018- (2023)
Summary: Background: Metastatic renal cell carcinoma (mRCC) is a heterogenous disease with poor 5-year overall survival (OS) at 14%. Patients with mRCC to endocrine organs historically have prolonged OS. Pancreatic metastases are uncommon overall, wi
Externí odkaz:
https://doaj.org/article/153c01ff313644d0bf2fd30f76560d5d
Autor:
Michiel S. van der Heijden, Thomas Powles, Daniel Petrylak, Ronald de Wit, Andrea Necchi, Cora N. Sternberg, Nobuaki Matsubara, Hiroyuki Nishiyama, Daniel Castellano, Syed A. Hussain, Aristotelis Bamias, Georgios Gakis, Jae-Lyun Lee, Scott T. Tagawa, Ulka Vaishampayan, Jeanny B. Aragon-Ching, Bernie J. Eigl, Rebecca R. Hozak, Erik R. Rasmussen, Meng Summer Xia, Ryan Rhodes, Sameera Wijayawardana, Katherine M. Bell-McGuinn, Amit Aggarwal, Alexandra Drakaki
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-15 (2022)
Identification of biomarkers to stratify patients who might benefit from treatment is needed to optimize targeted therapies. Here, based on an analysis of the RANGE trial (NCT02426125), the authors report potentially predictive biomarkers for surviva
Externí odkaz:
https://doaj.org/article/48cfab2e04994935a36166abe99febbf
Autor:
Bino Varghese, Steven Cen, Haris Zahoor, Imran Siddiqui, Manju Aron, Akash Sali, Suhn Rhie, Xiaomeng Lei, Marielena Rivas, Derek Liu, Darryl Hwang, David Quinn, Mihir Desai, Ulka Vaishampayan, Inderbir Gill, Vinay Duddalwar
Publikováno v:
European Journal of Radiology Open, Vol 9, Iss , Pp 100440- (2022)
Objectives: To identify computed tomography (CT)-based radiomic signatures of cluster of differentiation 8 (CD8)-T cell infiltration and programmed cell death ligand 1 (PD-L1) expression levels in patients with clear-cell renal cell carcinoma (ccRCC)
Externí odkaz:
https://doaj.org/article/90dae9be3c1247ed895c958fbfc62127
Autor:
Vivek Subbiah, Shivaani Kummar, Ulka Vaishampayan, Mark Chao, Sandip Patel, James Strauss, Lanjia Lin, Sonam Puri, Giri Ramsingh
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/2ac5f66024e24069a8aabb6c379fc032
Autor:
Ulka Vaishampayan, Patrick Schöffski, Alain Ravaud, Christian Borel, Julio Peguero, Jorge Chaves, John C. Morris, Nuria Kotecki, Martin Smakal, Dongli Zhou, Silke Guenther, Marcis Bajars, James L. Gulley
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-9 (2019)
Abstract Background Antibodies targeting programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) have shown clinical activity in the treatment of metastatic renal cell carcinoma (mRCC). This phase Ib cohort of the JAVELIN Solid Tumor trial ass
Externí odkaz:
https://doaj.org/article/f6a78bbebff642488c3eedc3f6c9cbae
Autor:
Cristiane Decat Bergerot, Paulo Gustavo Bergerot, Errol J. Philip, Jo Ann Hsu, Nazli Dizman, Ulka Vaishampayan, Tanya Dorff, Sumanta Kumar Pal
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-5 (2019)
Abstract Background Despite the advent of checkpoint inhibitors (CPIs) for advanced genitourinary (GU) cancers, existing studies suggest that durable complete responses are observed in fewer than 10% of patients. This study sought to evaluate the ass
Externí odkaz:
https://doaj.org/article/d8e7825f2ef047a18c3113a531308edf
Autor:
Ulka Vaishampayan, Darshana Patil, Wahida Rahman, Stephanie Patterson, Emilija Mitrikeska, Joe Dib
Publikováno v:
Cancer Research. 83:OT3-18
Introduction The Standard of Care for early detection of breast cancer in asymptomatic women is screening mammography, which has limitations such as radiation exposure and lower sensitivity to detect cancer in women with high breast density or invasi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9752508275386e8f20ec04aff073e766
https://doi.org/10.1158/1538-7445.sabcs22-ot3-18-02
https://doi.org/10.1158/1538-7445.sabcs22-ot3-18-02